Skip to main content
Premium Trial:

Request an Annual Quote

Courtagen, Scienion Ink Protein Biochip Deal

NEW YORK (GenomeWeb News) – Scienion US said today that array firm Courtagen Life Sciences will use Scienion's sciFlexArrayer technology to produce biochips for use with its Avantra Q400 Biomarker Workstation.

Courtagen will use the company's sciFlexArrayer S11 instrument to produce biochips for automated multiplex immunoassays for research and clinical use.

Courtagen was launched as Avantra Biosciences in December 2009 from the assets of defunct biomarker firm Decision Biomarkers. The company launched the Q400 as a research-only device in January 2011 along with its Angio Qx BioChip immunoassay for the study of tumor vascularization.

Last month, the company announced that it had submitted a pre-investigational device exemption information package to the US Food and Drug Administration for its Avantra Q400 Biomarker Workstation and its QPDX BioChip for the measurement of C-reactive protein.

"We have been looking for a reliable solution for the reproducible high throughput production of spotted arrays for our QPDx BioChips," Kate Sheldon, director of product development at Courtagen, said in a statement. "The Scienion sciFlexArrayer S11 is able to consistently produce high quality arrays that meet our needs and has the capacity to meet demand as our business grows."